מכפיל P/S עתידי: INVO Bioscience Inc. (INVO)

High equipment assembly costs create financial risks, as evidenced by the forward P/S history, where the ratio stands at 0.30. INVO Bioscience, Inc. (INVO) achieves cost optimization through contract manufacturing and external support. The current development vector is based on creating a digital network of reproduction clinics following a strategic merger, transforming the business model into a vertically integrated system.

Investors utilize forward multiples to verify an asset's market value relative to its future cash flows. The ratio of current price to expected revenue, illustrated by the forward P/S trend, allows for an assessment of whether INVO Bioscience (INVO) is overbought amid strict R&D pipeline optimization and a limited budget for device modernization, signaling the extent to which market expectations are justified.